Treatment of early stage Hodgkin’s disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone

  • P. J. O’Dwyer
  • P. H. Wiernik
  • M. B. Stewart
  • R. G. Slawson
Part of the Developments in Oncology book series (DION, volume 32)


In 1976, extended field megavoltage radiation had become standard therapy for Hodgkin’s disease confined to lymph nodes [1, 2]. While essentially all patients with Stage I disease are cured by this technique, it has become apparent that a significant number of patients with more advanced disease relapse after treatment with radiotherapy alone. This is especially true of Stage IIIA disease [3], and those with large mediastinal masses with or without extranodal extension into lung [4, 5], but among all Stages I and II, relapse rates as high as 27% have been reported [6]. The recognition that combination chemotherapy could prolong both duration of second remission and survival in patients relapsing after radiation therapy [6, 7], prompted the evaluation of several combined modality regimens as initial treatment in patients with Stages I to IIIA disease [8–12]. The apparent benefits of this approach in terms of remission duration [9], and the growing awareness of undesirable long-term toxic effects of combined modality therapy [13], prompted the present study. Interim analyses have been presented previously [14, 15].


Infective Endocarditis Combine Modality Constrictive Pericarditis Combine Modality Therapy Remission Duration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Peters MV (1950). A study of survivals in Hodgkin’s disease treated radiologically. Amer J Roentgenol 63: 299–311.Google Scholar
  2. 2.
    Kaplan HS (1980). Hodgkin’s disease: Unfolding concepts concerning its nature, management and prognosis. Cancer 45: 2439–2474.PubMedCrossRefGoogle Scholar
  3. 3.
    Hoppe RT, Rosenberg SA, Kaplan HS and Cox RS (1980). Prognostic factors in pathological Stage IIIA Hodgkin’s disease. Cancer 46: 1240–1246.PubMedCrossRefGoogle Scholar
  4. 4.
    Levi JA and Wiemik PH (1977) Limited extranodal Hodgkin’s disease: Unfavorable prognosis and therapeutic implications. Amer J Med 63: 365–372.PubMedCrossRefGoogle Scholar
  5. 5.
    Timothy AR, Sutcliff SBJ, Stansfeld AG et al. (1978). Radiotherapy in the treatment of Hodgkin’s disease. Br Med J 1: 1246–1249.PubMedCrossRefGoogle Scholar
  6. 6.
    Weller SA, Glatstein E, Kaplan HS and Rosenberg SA (1976). Initial relapses in previously treated Hodgkin’s disease. I. Results of second treatment. Cancer 37: 2840–1846.Google Scholar
  7. 7.
    Mintz U, Miller JB, Golomb HM et al. (1979). Pathologic Stage I and II Hodgkin’s disease, 1968–1975. Relapses and results of retreatment. Cancer 44: 72–79.Google Scholar
  8. 8.
    Rosenberg SA, Kaplan HS, Glatstein EJ and Portlock CS (1978). Combined modality therapy of Hodgkin’s disease. Cancer 42: 991–1000.PubMedCrossRefGoogle Scholar
  9. 9.
    Wiemik PH, Gustafson J, Schimpff SC and Diggs C (1979). Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Results eight years later. Amer J Med 67: 183–193.Google Scholar
  10. 10.
    Andrieu JM, Montagnon B, Asselain B et al. (1980). Chemotherapy-radiotherapy association in Hodgkin’s disease, Clinical Stages IA, II2A: Results of a prospective clinical trial with 166 patients. Cancer 46: 2126–2130.PubMedCrossRefGoogle Scholar
  11. 11.
    Hagemeister TB, Fuller LM, Velasquez WS et al. (1982). Stage I and II Hodgkin’s disease: Involved-field radiotherapy versus extended field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep 66: 789–798.PubMedGoogle Scholar
  12. 12.
    Nissen NI and Nordentoft AW (1982). Radiotherapy versus combined modality treatment of Stage I and II Hodgkin’s Disease. Cancer Treat Rep 66: 799–803.PubMedGoogle Scholar
  13. 13.
    Arseneau JC, Sponzo RW, Levin DL et al. (1972). Non-lymphomatous malignant tumors complicating Hodgkin’s disease. N Engl J Med 287: 1119–1122.PubMedCrossRefGoogle Scholar
  14. 14.
    Wiemik PH, Slawson RG, Burks LC and Diggs CH (1979). A randomized trial of radiotherapy (R) and MOPP ( C) versus MOPP alone for Stage IB to IIIA Hodgkin’s disease. Proc Amer Soc Clin Oncol 17: 314.Google Scholar
  15. 15.
    O’Dwyer PJ, Wiemik PH, Finlay R and Ungerleider RS (1983). A randomized trial of radiotherapy (RT) and MOPP ( C) vs MOPP alone for Stages IB-IIIA Hodgkin’s disease. Proc Amer Soc Clin Oncol 2: 214.Google Scholar
  16. 16.
    DeVita VT, Serpick AA and Carbone PP (1970). Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73: 881–895.PubMedGoogle Scholar
  17. 17.
    Carbone PP, Kaplan HS, Musshoff K et al. (1971). Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31: 1860–1861.PubMedGoogle Scholar
  18. 18.
    Lukes RJ and Butler JJ (1966). The pathology and nomenclature of Hodgkin’s disease. Cancer Res 26: 1063–1081.PubMedGoogle Scholar
  19. 19.
    Wiernik PH and Slawson RG (1982). Hodgkin’s disease with direct extension into pulmonary parenchyma from a mediastinal mass: A presentation requiring special therapeutic considerations. Cancer Treat Rep 66: 711–716.PubMedGoogle Scholar
  20. 20.
    Stein RS, Golomb HM, Wiernik PH et al. (1982). Anatomic substages of Stage IIIA Hodgkin’s disease: Followup of a collaborative study. Cancer Treat Rep 66: 733–741.PubMedGoogle Scholar
  21. 21.
    Coleman CN, Williams CJ, Flint A et al. (1977). Hematologic neoplasia in patients treated for Hodgkin’s disease. N Engl J Med 297: 1249–1252.PubMedCrossRefGoogle Scholar
  22. 22.
    Krikorian JG, Burke JS Rosenberg SA and Kaplan HS (1979). The occurrence of non-Hodgkin’s lymphoma following therapy for Hodgkin’s disease. N Engl J Med 300: 452–458.PubMedCrossRefGoogle Scholar
  23. 23.
    Bonadonna G (1982). Chemotherapy strategies to improve the control of Hodgkin’s disease: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 42: 4309–4320.PubMedGoogle Scholar
  24. 24.
    Moore MR, Bull JM, Jones SE et al. (1972). Sequential radiotherapy and chemotherapy in the treatment of Hodgkin’s disease: A progress report. Ann Intern Med 77: 1–9.Google Scholar
  25. 25.
    Schimpff SC, O’Connell MJ, Greene WH and Wiernik PH (1975). Infections in 92 splenectomized patients with Hodgkin’s disease. Ann Intern Med 59: 695–701.Google Scholar
  26. 26.
    Glicksman AS and Nickson JJ (1973). Acute and late reactions to irradiation in the treatment of Hodgkin’s disease. Arch Int Med 131: 369–373.CrossRefGoogle Scholar
  27. 27.
    Stewart HR, Cohn KE, Fajardo LF et al. (1967). Radiation-induced heart disease: A study of twenty-five patients. Radiology 89: 302–310.Google Scholar
  28. 28.
    Applefeld MM, Slawson RG, Spicer KM et al. (1982). Long-term cardiovascular evaluation of patients with Hodgkin’s disease treated by thoracic mantle radiation therapy. Cancer Treat Rep 66: 1003–1013.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • P. J. O’Dwyer
    • 1
  • P. H. Wiernik
    • 1
  • M. B. Stewart
    • 1
  • R. G. Slawson
    • 1
  1. 1.University of Maryland Cancer Center (formerly Baltimore Cancer Research Center)BaltimoreUSA

Personalised recommendations